Skip to main content
. 2022 Jun 28;14(6):401–413. doi: 10.1111/1753-0407.13286

FIGURE 1.

FIGURE 1

Trial design.

AGI, alpha glucosidase inhibitor; degludec, insulin degludec; IDegLira, insulin degludec/liraglutide; OAD, oral antidiabetic drug; SU, sulphonylurea; TZD, thiazolidinedione; V, visit.